Pathological subtype dictates survival and failure pattern in laryngeal neuroendocrine neoplasms
Laryngeal cancer subtype determines survival patterns, providing evidence-based guidance for this rare head-neck malignancy.
This retrospective study of laryngeal neuroendocrine neoplasms—constituting under 1% of laryngeal cancers—demonstrates that pathological subtype dictates survival outcomes and failure patterns, providing rare evidence-based guidance for this ultra-rare malignancy with no established standard of care. The findings support subtype-stratified treatment planning and highlight the need for larger registries in rare head-neck neuroendocrine tumors.
What the study was
- Study design
- Retrospective clinical outcomes study
- Population
- Patients with laryngeal neuroendocrine neoplasms (< 1% of laryngeal malignancies)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- World journal of surgical oncology
Why it surfaced
Rare disease with <1% prevalence among laryngeal malignancies; pathological subtype data fills a major evidence gap for this ultra-rare head-neck NEN.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.